$ASPI

ASP Isotopes Inc. (ASPI): Entry into a Material Definitive Agreement

ASP Isotopes Inc. (ASPI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 aspi_ex101.htm FORM OF SECURITIES EXCHANGE AGREEMENT aspi_ex101.htm EXHIBIT 10.1 FORM OF SECURITIES EXCHANGE AGREEMENT This Securities Exchange Agreement (this “ Agreement ”), dated as of July 15, 2026 (the “ Effective Date ”), is entered into by and between ASP Isotope

Original reporting
Published Jul 16, 2026, 1:58 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 10:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$ASPI
Neutral
medium confidence
Mentioned
$ASPI
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ASPINeutralMed
01

Why it matters

ASPI will exchange a holder’s 8% convertible promissory note (due Nov 19, 2030) for common stock calculated using an exchange price of $4.96, with closing on or before 9:00 a.m. ET July 31, 2026. Delivery of shares may be delayed up to 10 business days due to DTC/transfer agent mechanics.

02

Market read

This is a capital-structure event that can affect ASPI’s near-term trading via dilution expectations and execution timing.

03

What to watch

The filing excerpt does not provide the exchanged note principal amount or total shares to be issued, which are key inputs for estimating dilution and valuation impact.

Relevance 6/10Novelty 6/10Timing: Ahead of the July 31, 2026 closing date for the note exchange.

Background

The 8-K reports Item 1.01 and Item 3.02, including an exhibit describing a securities exchange agreement dated July 15, 2026.

Company-level read

Ticker impact

$ASPINeutralMedium confidence
Context

ASPI entered a material definitive securities exchange agreement to swap an 8% convertible note into common stock at an exchange price of $4.96.

Expected impact

Near-term volatility possible around the July 31, 2026 closing and any subsequent share issuance mechanics; direction depends on whether the market views the exchange as debt relief versus dilution.

Evidence & confidence

The 8-K is a primary disclosure of a note-for-equity exchange with a fixed exchange price ($4.96) and a defined closing date, but the article does not state total principal size or expected dilution magnitude.

Market effects

Limited sector read-through; this is company-specific capital structure management.

No clear regional spillover indicated by the filing.

No global macro or cross-border transaction details provided.

Counterpoint

If the exchange reduces cash interest burden or improves balance-sheet optics, the market could interpret it as credit-risk mitigation rather than pure dilution.

Key entities

  • ASP Isotopes Inc.

    Company entering the securities exchange agreement to swap a convertible note for common stock.

  • Quantum Leap Energy LLC

    Entity party to the exchange agreement and referenced in the original note issuance context.

Related articles

$ASPIMed

ASP Isotopes Secures Five-Year LNG Offtake for Virginia Gas Project

ASP Isotopes said Tetra4, a subsidiary of Renergen, signed a five-year take-or-pay LNG offtake for its Virginia Gas Project in South Africa. The deal covers about 10% of Phase 1 capacity, priced above $16 per GJ, and supports revenue certainty. Phase 1 targets ~2,500 GJ/day LNG and ~70 Mcf/day helium, with operations in Q3 2026; Phase 1 revenue could exceed $27M annually.

$ASPIMed

ASP Isotopes Inc. (ASPI): Results of Operations and Financial Condition

ASP Isotopes Inc. (ASPI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aspi-ex99_1.htm EX-99.1 EX-99.1 EXHIBIT 99.1 ASP Isotopes Issues Letter to Shareholders DALLAS, August 4, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes”, “ASPI” or the “Company”), an advanced materials company focused on developing technologie

$ASPIMed

ASPI Stock Heads For Best Gains In 7 Months – Why Are Investors Excited About ASP Isotopes Restarting Its Silicon Facility?

ASP Isotopes (ASPI) said it restarted its Silicon-28 silicon enrichment facility in South Africa after nearly a year of optimization to meet customer expectations. The company reported the first 18 stages have operated for over three weeks at target enrichment levels and expects to fulfill U.S. supply agreements in Q3. ASPI shares rose more than 24% Tuesday.

$ASPIMed

ASP Isotopes targets September helium deliveries as chip demand grows

ASP Isotopes said it expects commercial helium deliveries from its South African project to start in September, as semiconductor demand rises and supply disruptions in Qatar and Russia push chipmakers to diversify. CEO Paul Mann expects phase 1 to reach nameplate capacity in Q3. The company’s first commercial offtake is priced above $600 per thousand cubic feet, up from about $400 a year ago.

$ASPIMed

ASP Isotopes Announces Agreements to Exchange Certain QLE Convertible Notes for ASPI Common Stock

ASP Isotopes (NASDAQ: ASPI) said it entered private exchange agreements with holders of Quantum Leap Energy LLC’s QLE convertible promissory notes. Holders will exchange about $109.2 million of notes plus accrued interest for about 23.2 million ASPI shares, about 17.8% of ASPI’s shares. The deal cuts QLE notes by about 50% to $110.7 million, expected to close July 16, 2026.

$ASPIMedAI 8/10

ASP Isotopes proposes merger of Noble Africa with EBDRA Life Sciences

ASP Isotopes (JSE, Nasdaq) said its wholly owned subsidiary Noble Africa will merge with a subsidiary of ENDRA Life Sciences, with Noble Africa as the surviving entity. The combined company plans to trade on Nasdaq as “Noble Africa Inc” under ticker NOBA. A private placement is expected to raise about $50m gross, including ~$20m from ASP Isotopes. ASP Isotopes expects ~89% ownership; deal expected Q3/Q4 pending SEC registration and approvals.